ArticleJournal of biomedical science2025
Surface charge of the C-terminal helix is crucial for antibacterial activity of endolysin against Gram-negative bacteria.
Article in Journal of biomedical science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Construction and Characterization of the Novel Engineered Endolysin ALC005: A New Alternative Antimicrobial AgainstMicroorganisms · 2026Article
- Cationic Liposome-Fused Endolysin Lys40 Overcomes Outer Membrane Barriers and Enhances Survival inAnimals : an open access journal from MDPI · 2026Article
- Experimental screening and structure-informed engineering of peptide-fused bacteriophage lysins with enhanced activity against Gram-negative bacteria.Frontiers in pharmacology · 2026Article
- Expanding structural insights into DNA packaging apparatus and endolysin LysSA05 function of Epsilon15 bacteriophage.Frontiers in cellular and infection microbiology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundsEndolysins are promising alternatives to antibiotics because they can lyse bacterial cells rapidly with a low risk of resistance development, however, their effectiveness against Gram-negative bacteria is hindered by the presence of the outer membrane present in Gram-negative bacteria. Several endolysins with amphipathic helices at the C-terminus have been reported to have intrinsic antibacterial activity against Gram-negative bacteria but their action mechanism is not fully elucidated.
methodsThe sequence alignment analysis was assessed with the CLC Main workbench 7, and His-tagged endolysins were purified with affinity chromatography. Site-directed mutagenesis was used to generate mutations in the endolysin to make various endolysin mutants. The muralytic activity of the endolysin against Gram-negative bacteria was analyzed using a turbidity reduction assay and the antibacterial activities of the endolysins were assessed through a viable cell counting assay.
resultsWe identified two endolysins, LysTS3 and LysTS6, both of which have similar sequences and structures including the amphipathic helices at their C-terminus. LysTS6 exhibited significantly higher antibacterial activity against Gram-negative bacteria compared to LysTS3 even though both enzymes have similar muralytic activity against the outer membrane-permeabilized Gram-negative bacteria. Systematic truncation and bioinformatic analysis of these two endolysins revealed a major difference in the charge on the surface of their C-terminal helices, suggesting the possibility that the charge on this helix can determine the antibacterial activity of the endolysins against Gram-negative bacteria. We could enhance the activity of LysTS3 against Gram-negative bacteria by replacing Ala
conclusionsThe antibacterial activity of endolysin against Gram-negative bacteria could be enhanced by adjusting the surface charge on the C-terminal amphipathic helix to more positive, suggesting that the positive surface charge on the C-terminal amphipathic helix of endolysin is crucial for its penetration of outer membrane to reach peptidoglycan layer of Gram-negative bacteria.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.